Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + valproic acid + carboplatin
- Development stage
- Discontinued
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
A combination regimen consisting of azacitidine, valproic acid, and carboplatin. This therapeutic approach, investigated by the M.D. Anderson Cancer Center, aims to treat platinum-resistant epithelial ovarian cancer. The strategy utilizes azacitidine (a DNA methyltransferase inhibitor) and valproic acid (a histone deacetylase inhibitor) as epigenetic priming agents to sensitize tumor cells to the cytotoxic effects of carboplatin (a platinum-based DNA alkylating agent). By reversing DNA methylation and histone deacetylation, the combination seeks to restore the expression of genes involved in apoptosis and platinum sensitivity, potentially overcoming resistance mechanisms in advanced solid tumors.
- Other names
- Azacitidine, Valproic Acid, and Carboplatin
02
Targets
DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)HDAC (HDAC family)
Beyond the preview
Go deeper on azacitidine + valproic acid + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + valproic acid + carboplatin.